Profile data is unavailable for this security.
About the company
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
- Revenue in USD (TTM)25.81m
- Net income in USD-65.01m
- Incorporated1994
- Employees116.00
- LocationSilence Therapeutics PLC72 Hammersmith RoadLONDON W14 8THUnited KingdomGBR
- Phone+44 203 457 6900
- Fax+44 795 731 8494
- Websitehttps://www.silence-therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shattuck Labs Inc | 1.00m | -54.90m | 253.12m | 44.00 | -- | 2.71 | -- | 253.12 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| OmniAB Inc | 21.09m | -63.67m | 253.36m | 114.00 | -- | 0.9132 | -- | 12.01 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 255.12m | 34.00 | -- | 9.80 | -- | 13.45 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 269.70m | 8.00 | -- | 5.14 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Silence Therapeutics PLC - ADR | 25.81m | -65.01m | 282.46m | 116.00 | -- | 3.81 | -- | 10.94 | -1.39 | -1.39 | 0.5493 | 1.57 | 0.1383 | -- | 124.98 | 222,511.00 | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 289.64m | 275.00 | -- | 0.0316 | -- | 1.28 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 293.63m | 124.00 | -- | 1.73 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 298.59m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 299.66m | 110.00 | -- | -- | -- | 7.45 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 300.49m | 71.00 | -- | 2.34 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 308.24m | 28.00 | -- | 1.74 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 308.64m | 4.00 | -- | 1.38 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 309.32m | 104.00 | -- | 1.20 | -- | 8.60 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
Data as of Mar 03 2026. Currency figures normalised to Silence Therapeutics PLC's reporting currency: US Dollar USD
16.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2025 | 2.16m | 4.58% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 1.54m | 3.27% |
| Ikarian Capital LLCas of 31 Dec 2025 | 865.78k | 1.83% |
| Great Point Partners LLCas of 31 Dec 2025 | 808.03k | 1.71% |
| Millennium Management LLCas of 31 Dec 2025 | 659.59k | 1.40% |
| Medical Strategy GmbHas of 30 Dec 2025 | 528.01k | 1.12% |
| Tetragon Partners UK LLPas of 31 Dec 2025 | 365.37k | 0.77% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 298.78k | 0.63% |
| SG Americas Securities LLCas of 31 Dec 2025 | 256.34k | 0.54% |
| Lombard Odier Asset Management (USA) Corp.as of 31 Dec 2025 | 255.90k | 0.54% |
More ▼
Data from 30 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
